Impax Pharmaceuticals, the branded products division of Impax Laboratories Inc. (IPXL), announced that the U.S. FDA has extended the PDUFA date for its review of the RYTARY (IPX066) New Drug Application from October 9, 2014, to January 9, 2015. RYTARY is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease.
The company amended the chemical, manufacturing and control section of the RYTARY NDA subsequent to its submission of responses to the July 26, 2014 Form 483 observations at the Taiwan facility. The FDA notified the company that such amendment constituted a major amendment, and has extended the PDUFA date to review the additional information.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.